Source: Annual Congress 2001 - Pathophysiology of OSA
Disease area: Sleep and breathing disorders



Rating:

Share or cite this content

Citations should be made in the following way:
M. A. Machnick, M. Haske, C. Flashar, W. Zidek, B. Sanner (Herne, Germany). Leptin in obstructive sleep apnea. Eur Respir J 2001; 16: Suppl. 31, 2215

Member's Comments

No comment yet.

Related content which might interest you: Cortisol metabolism in obstructive sleep apnea (OSA) Source: Eur Respir J 2002; 20: Suppl. 38, 215s Year: 2002 Catecholamine secretion in obstructive sleep apnoea (OSA) Source: Eur Respir J 2005; 26: Suppl. 49, 38s Year: 2005 Can leptin be used to treat obstructive sleep apnoea? Source: International Congress 2019 – New horizons for pharmacotherapy of sleep-disordered breathing: from bench to bedside Year: 2019 Hypertension and obstructive sleep apnoea Source: Annual Congress 2006 - Obstructive sleep apnoea and cardiovascular diseases Year: 2006 Metabolic syndrome in obstructive sleep apnoea patients Source: Annual Congress 2007 - Sleep apnoea Year: 2007 The velumount device for obstructive sleep apnoea Source: Annual Congress 2009 - Assessment and therapeutical interventions in obstructive sleep apnoea Year: 2009 Leptin and ghrelin levels in patients with obstructive sleep apnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 332s Year: 2004 Insulin resistance in obstructive sleep apnea patients Source: Annual Congress 2010 - Pulmonary circulation III Year: 2010 Albuminuria in children with obstructive sleep apnea Source: Annual Congress 2011 - Obstructive sleep apnoea: inflammation and metabolism Year: 2011 Change in PLMS after treatment of obstructive sleep apnea Source: Eur Respir J 2007; 30: Suppl. 51, 593s Year: 2007 Screening for obstructive sleep apnea (OSA) in acromegaly Source: Virtual Congress 2020 – Screening methods and diagnostic tools for obstructive sleep apnoea Year: 2020 Pathophysiological consequences of obstructive sleep apnoea Source: Annual Congress 2006 - Obstructive sleep apnoea and cardiovascular diseases Year: 2006 NT-proBNP in obstructive sleep apnoea (OSA) Source: Eur Respir J 2006; 28: Suppl. 50, 415s Year: 2006 Awakening headaches are associated with obstructive sleep apnea Source: Eur Respir J 2002; 20: Suppl. 38, 452s Year: 2002 Comorbidities of obstructive sleep apnoea syndrome Source: Annual Congress 2011 - Comorbid obstructive sleep apnoea (OSA) and OSA comorbidities Year: 2011 ACE-inhibitors and obstructive sleep apnoea Source: Eur Respir J 2005; 26: Suppl. 49, 358s Year: 2005 Prevalence of complex sleep apnea among German patients with obstructive sleep apnea Source: Annual Congress 2009 - Socio-economic and epidemiological aspects of sleep apnoea Year: 2009 The inflammation and insulin resistance in obstructive sleep apnea Source: Annual Congress 2012 - Metabolic and cardiovascular consequences of OSA I Year: 2012 Ato-oxy as the first successful pharmacotherapy for obstructive sleep apnoea Source: International Congress 2019 – New horizons for pharmacotherapy of sleep-disordered breathing: from bench to bedside Year: 2019 Predictors of hypercapnia in obstructive sleep apnoea (OSA) Source: Annual Congress 2010 - Lung disease and mountain sickness: the importance of ventilatory control Year: 2010